KEY TAKEAWAYS: 70% of Sponsors miss their milestones by an average of eight months, suggesting the clinical trial recruitment ...

A London-based biotech has emerged from stealth with a personalized T cell therapy platform that it says could create ...

Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what ...

Five months after the FDA blocked its plans for accelerated approval, Agenus is moving ahead with discussions with potential ...

President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

Merck's Keytruda and Eisai's Lenvima combo with chemo failed survival endpoint in gastroesophageal cancer study, but ...

Aardvark Therapeutics files for IPO. Company develops hunger-targeting obesity drug ARD-101 and ARD-201, led by CEO Tien Lee.

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

The FDA dodged claims from Vanda Pharmaceuticals that it allegedly violated the US Constitution by recommending the same drug ...

Moderna’s chief information officer Brad Miller is 'retiring' in February, a company spokesperson confirmed to Endpoints News ...

UnitedHealth Group has named a new CEO to lead its health insurance business, following the murder of the division’s former ...